| Pharmacogenomics in the era of next generation sequencing–from byte to bedside LE Russell, Y Zhou, AA Almousa, JK Sodhi, CK Nwabufo, VM Lauschke Drug Metabolism Reviews 53 (2), 253-278, 2021 | 30 | 2021 |
| Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease CK Nwabufo, OP Aigbogun Journal of neurology 269 (11), 5762-5786, 2022 | 15 | 2022 |
| Relevance of ABC transporters in drug development CK Nwabufo Current Drug Metabolism 23 (6), 434-446, 2022 | 10 | 2022 |
| Employing in vitro metabolism to guide design of F-labelled PET probes of novel α-synuclein binding bifunctional compounds CK Nwabufo, OP Aigbogun, KJH Allen, MN Owens, JS Lee, CP Phenix, ... Xenobiotica 51 (8), 885-900, 2021 | 10 | 2021 |
| Bioanalytical strategies in drug discovery and development A Thakur, Z Tan, T Kameyama, E El-Khateeb, S Nagpal, S Malone, ... Drug Metabolism Reviews 53 (3), 434-458, 2021 | 10 | 2021 |
| Advances in the study of drug metabolism–symposium report of the 12th Meeting of the International Society for the Study of Xenobiotics (ISSX) LE Russell, MA Schleiff, E Gonzalez, AG Bart, F Broccatelli, JH Hartman, ... Drug metabolism reviews 52 (3), 395-407, 2020 | 7 | 2020 |
| Tandem mass spectrometric analysis of novel caffeine scaffold‐based bifunctional compounds for Parkinson's disease CK Nwabufo, A El‐Aneed, ES Krol Rapid communications in mass spectrometry 33 (23), 1792-1803, 2019 | 7 | 2019 |
| Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs CK Nwabufo, R Bendayan Trends in Pharmacological Sciences 43 (12), 1041-1054, 2022 | 6 | 2022 |
| Introduction to the mini special issue on next generation drug discovery and development: rethinking translational pharmacology for accelerated drug development CK Nwabufo Drug Metabolism Reviews 53 (2), 171-172, 2021 | 6 | 2021 |
| Biochemical effect of Hibiscus sabdariffa Calyx extracts on the reproductive hormones of male Wistar rat C Nwabufo, O Olusanya Advances in Applied Science Research 8 (2), 38-41, 2017 | 6 | 2017 |
| SARS-CoV-2 infection dysregulates the expression of clinically relevant drug metabolizing enzymes in Vero E6 cells and membrane transporters in human lung tissues CK Nwabufo, MT Hoque, L Yip, M Khara, S Mubareka, MS Pollanen, ... Frontiers in Pharmacology 14, 1124693, 2023 | 5 | 2023 |
| Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations CK Nwabufo Cancer Chemotherapy and Pharmacology 93 (2), 89-105, 2024 | 4 | 2024 |
| Potential application of mass spectrometry imaging in pharmacokinetic studies CK Nwabufo, OP Aigbogun Xenobiotica 52 (8), 811-827, 2022 | 4 | 2022 |
| Unraveling the metabolic fate of potential therapeutic dimer compounds for Parkinson’s disease C Nwabufo, E Krol Drug Metabolism and Pharmacokinetics 34 (1), S59-S60, 2019 | 4 | 2019 |
| An HPLC-UV validated bioanalytical method for measurement of in vitro phase 1 kinetics of α-synuclein binding bifunctional compounds OP Aigbogun, CK Nwabufo, MN Owens, KJH Allen, JS Lee, CP Phenix, ... Xenobiotica 52 (8), 916-927, 2022 | 1 | 2022 |
| Healthcare provider and patient perspectives on the implementation of pharmacogenetic-guided treatment in routine clinical practice G Kaur, CK Nwabufo Pharmacogenetics and Genomics, 10.1097, 2024 | | 2024 |
| COVID‐19 severity gradient differentially dysregulates clinically relevant drug processing genes in nasopharyngeal swab samples CK Nwabufo, J Luc, A McGeer, JA Hirota, S Mubareka, AC Doxey, ... British Journal of Clinical Pharmacology, 2024 | | 2024 |
| Preclinical Development of Novel Bifunctional Compounds for Parkinson's Disease CK Nwabufo University of Saskatchewan, 2019 | | 2019 |
